Skip to main content
. 2019 Oct 17;71(7):1655–1663. doi: 10.1093/cid/ciz1027

Table 1.

Baseline Demographic and Clinical Characteristics by Treatment Arm

Characteristic ART + PL (n = 29) ART + ZOL (n = 34)
Age, mean (SD), years 39.4 (6.9) 39.7 (6.6)
Sex, n (%)
 Male 23 (79.3) 27 (79.4)
 Female 6 (20.7) 7 (20.6)
Race, n (%)
 White 3 (10.3) 7 (20.6)
 Black 26 (89.7) 27 (79.4)
History of smoking, n (%)
 Yes 26 (89.7) 24 (70.6)
 No 3 (10.3) 10 (29.4)
Current smoking, n (%)
 Yes 23 (79.3) 19 (55.9)
 No 6 (20.7) 15 (44.1)
No. of cigarettes smoked per day (in patients with history of smoking), mean (SD) 7.6 (4.5) 7.5 (6.0)
Years of cigarette smoking (in patients with history of smoking), mean (SD) 13.4 (8.1) 13.9 (9.6)
Alcohol use in past 30 days, n (%)
 Daily 1 (3.4) 2 (5.9)
 56 times/wk 0 (0) 1 (2.9)
 34 times/wk 1 (3.4) 4 (11.8)
 12 times/wk 8 (27.6) 3 (8.8)
 23 times/mo 2 (6.9) 2 (5.9)
 Once/month 3 (10.3) 8 (23.5)
 Never 14 (48.3) 14 (41.2)
Baseline osteopenia in any area,a n (%)
 Yes 10 (34.5) 7 (21.9)
 No 19 (65.6) 25 (78.1)
Baseline lumbar spine BMD, mean (SD)
 g/cm3 1.23 (0.14) 1.29 (0.14)
t score 0.16 (1.16) 0.67 (1.22)
History of bone fracture, n (%)
 Yes 5 (17.2) 10 (29.4)
 No 24 (82.8) 24 (70.6)
HIV-1 RNA, mean (SD), log10 copies/mL 4.81 (0.96) 5.26 (0.44)
CD4+ count, mean (SD), cells/µL 155 (145) 102 (69)
Serum calcium, mean (SD), mg/dL 9.3 (0.4) 9.1 (0.4)
Serum vitamin D, mean (SD), ng/mL 27.8 (10.0) 28.1 (11.7)

Data are presented as n (%) unless otherwise indicated.

Abbreviations: ART, antiretroviral therapy; BMD, bone mineral density; HIV, human immunodeficiency virus; PL, active placebo; SD, standard deviation; ZOL, zoledronic acid.

aPatients with osteoporosis were not enrolled in the study. Baseline dual-energy X-ray absorptiometry measurements for 2 patients were performed with a different machine and were not included in the analyses.